• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Silent Myocardial Infarction: A Case Report
We present a case of a 59-year-old overweight woman with prediabetes, primary hypertension, and hypercholesterolemia who presented for herpes zoster (HZ) follow-up; she reported having skipped heartbeats and heart rate fluctuations during the review of systems. On further workup, ECG revealed low voltage QRS complexes, flat QRS complexes, flat T waves, and pathological Q waves, suggesting the diagnosis of SMI. Based on the identified risk factors, including high BMI, prediabetes, primary hypertension, hypercholesterolemia, HZ, and newly diagnosed SMI, the patient was advised to continue with lisinopril 20 mg daily, prescri...
Source: Herpes - August 28, 2023 Category: Infectious Diseases Authors: Maria V Kolesova Suzanne Minor Source Type: research

Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial)
Introduction The world is undergoing a demographic transition to an older population. Preventive healthcare has reduced the burden of chronic illness at younger ages but there is limited evidence that these advances can improve health at older ages. Statins are one class of drug with the potential to prevent or delay the onset of several causes of incapacity in older age, particularly major cardiovascular disease (CVD). This paper presents the protocol for the STAtins in Reducing Events in the Elderly (STAREE) trial, a randomised double-blind placebo-controlled trial examining the effects of statins in community dwelling o...
Source: BMJ Open - April 3, 2023 Category: General Medicine Authors: Zoungas, S., Curtis, A., Spark, S., Wolfe, R., McNeil, J. J., Beilin, L., Chong, T. T.-J., Cloud, G., Hopper, I., Kost, A., Nelson, M., Nicholls, S. J., Reid, C. M., Ryan, J., Tonkin, A., Ward, S. A., Wierzbicki, A., On behalf of STAREE investigator group Tags: Open access, Cardiovascular medicine Source Type: research

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Publication date: 24–30 August 2019Source: The Lancet, Volume 394, Issue 10199Author(s): Gholamreza Roshandel, Masoud Khoshnia, Hossein Poustchi, Karla Hemming, Farin Kamangar, Abdolsamad Gharavi, Mohammad Reza Ostovaneh, Alireza Nateghi, Masoud Majed, Behrooz Navabakhsh, Shahin Merat, Akram Pourshams, Mahdi Nalini, Fatemeh Malekzadeh, Masoumeh Sadeghi, Noushin Mohammadifard, Nizal Sarrafzadegan, Mohammad Naemi-Tabiei, Abdolreza Fazel, Paul BrennanSummaryBackgroundA fixed-dose combination therapy (polypill strategy) has been proposed as an approach to reduce the burden of cardiovascular disease, especially in low-income ...
Source: The Lancet - August 23, 2019 Category: General Medicine Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Conclusions -Heretofore unknown effects of torcetrapib were revealed in immune and inflammatory functions. A protein-based risk score predicted harm from torcetrapib within just 3 months. A protein-based risk assessment embedded within a large proteomic survey may prove to be useful in the evaluation of therapies to prevent harm to patients. Clinical Trial Registration -URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00134264. PMID: 28974520 [PubMed - as supplied by publisher]
Source: Circulation - October 3, 2017 Category: Cardiology Authors: Williams SA, Murthy AC, DeLisle RK, Hyde C, Malarstig A, Ostroff R, Weiss SJ, Segal MR, Ganz P Tags: Circulation Source Type: research

Comparative Effectiveness of Generic Atorvastatin and Lipitor(R) in Patients Hospitalized with an Acute Coronary Syndrome Health Services and Outcomes Research
Conclusions Among older adults discharged alive after ACS hospitalization, we found no significant difference in cardiovascular outcomes or serious, infrequent side effects in patients prescribed generic atorvastatin compared with those prescribed Lipitor® at 1 year. Our findings support the use of generic atorvastatin in ACS, which could lead to substantial cost saving for patients and health care plans without diminishing population clinical effectiveness.
Source: JAHA:Journal of the American Heart Association - April 18, 2016 Category: Cardiology Authors: Jackevicius, C. A., Tu, J. V., Krumholz, H. M., Austin, P. C., Ross, J. S., Stukel, T. A., Koh, M., Chong, A., Ko, D. T. Tags: Atrial Fibrillation, Quality and Outcomes Health Services and Outcomes Research Source Type: research

Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial
Conclusion The infrastructure of GCS and the primary health care system in Iran enabled the conduct of this pragmatic large-scale trial. If the polypill strategy proves effective, it may be implemented to prevent cardiovascular disease in developing countries.
Source: European Journal of Preventive Cardiology - November 9, 2015 Category: Cardiology Authors: Ostovaneh, M. R., Poustchi, H., Hemming, K., Marjani, H., Pourshams, A., Nateghi, A., Majed, M., Navabakhsh, B., Khoshnia, M., Jaafari, E., Mohammadifard, N., Malekzadeh, F., Merat, S., Sadeghi, M., Naemi, M., Etemadi, A., Thomas, G. N., Sarrafzadegan, N. Tags: Original scientific paper Source Type: research

High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis
Conclusions High-intensity statin therapy could effectively reduce the risk of stroke in patients with CKD. However, its effects on all-cause mortality, myocardial infarction, heart failure and renal protection remain unclear. Moreover, it is hard to draw conclusions on the safety assessment of intensive statin treatment in this particular population. More studies are needed to credibly evaluate the effects of high-intensity statin therapy in patients with CKD.
Source: BMJ Open - May 15, 2015 Category: Journals (General) Authors: Yan, Y.-L., Qiu, B., Wang, J., Deng, S.-B., Wu, L., Jing, X.-D., Du, J.-L., Liu, Y.-J., She, Q. Tags: Open access, Cardiovascular medicine, Pharmacology and therapeutics Research Source Type: research

Assessment of Lipophilic vs. Hydrophilic Statin Therapy in Acute Myocardial Infarction.
Conclusions:On 2-year comparison of hydrophilic and lipophilic statins there was no significant difference in prevention of secondary cardiovascular outcome. PMID: 25392071 [PubMed - as supplied by publisher]
Source: Circulation Journal - November 12, 2014 Category: Cardiology Authors: Izawa A, Kashima Y, Miura T, Ebisawa S, Kitabayashi H, Yamamoto H, Sakurai S, Kagoshima M, Tomita T, Miyashita Y, Koyama J, Ikeda U Tags: Circ J Source Type: research

Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial
Conclusion In subjects with TRH, intensive lipid lowering with atorvastatin 80 mg is associated with a significant reduction in cardiovascular events.
Source: European Heart Journal - July 15, 2014 Category: Cardiology Authors: Bangalore, S., Fayyad, R., Laskey, R., DeMicco, D., Deedwania, P., Kostis, J. B., Messerli, F. H., Treating to New Targets Steering Committee and Investigators Tags: Heart failure/cardiomyopathy Source Type: research

The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial
Abstract: Background: Current guidelines recommend intensive low-density lipoprotein (LDL) cholesterol lowering with statins, with a target of 70mg/dL (1.81mmol/L) LDL cholesterol for those with a very high risk of coronary artery events. However, there is no multicenter study assessing the effect of intensive lipid-lowering therapy with statins on acute coronary syndrome (ACS) in a Chinese population with low baseline LDL cholesterol levels.Methods and results: Patients (n=1355) with ACS were treated with a moderate dose of statin (atorvastatin 10 mg/d, or equivalent dose of other statins, n=675) or with an intensive dose...
Source: Atherosclerosis - March 20, 2014 Category: Cardiology Authors: Shui-ping Zhao, Bi-lian Yu, Dao-quan Peng, Yong Huo Tags: Clinical & Population Research – Intervention Source Type: research